Hub : Traits :

Heart attack/myocardial infarction (self-reported)

48 significantly associated models · 15 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 109098737 110517617 3 1 5.4e-09 3.9e-09 1.0e+00 100 PSRC1
2 1 222096959 223567803 3 1 2.4e-12 3.5e-12 1.0e+00 100 RP11-378J18.8
3 3 135861666 137253713 1 1 2.8e-07 1.1e-07 8.0e-02 89 RP11-731C17.2
4 6 12020241 13990267 2 1 1.1e-16 1.0e-16 3.8e-02 94 RP1-257A7.5
5 6 159820779 161571560 2 2 5.3e-09 4.8e-12 1.3e-08 32 RP11-288H12.3 SLC22A3
6 9 21303958 22819407 2 2 7.3e-16 6.8e-31 8.3e-16 52 CDKN2B CDKN2B-AS1
7 15 90730363 92135418 1 1 3.6e-08 2.8e-06 5.6e-01 98 FES

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.81 1 0 0.0 0.00 1.0e+00 FES
Bipolar Disorder or Schizophrenia 4.18 2 1 2.2 0.00 1.0e+00 FES RP11-731C17.2
Neuroticism (Nagel 2018) 1.21 1 0 0.0 0.00 1.0e+00 FES
Schizophrenia (2018) 4.38 2 1 2.2 0.00 1.0e+00 FES RP11-731C17.2
Worry (Nagel 2018) 1.30 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Breast Cancer 3.13 3 0 0.0 0.00 1.0e+00 CDKN2B CDKN2B-AS1 FES
Coronary Artery Disease (CAD) 31.53 5 4 8.9 0.99 1.6e-03 CDKN2B CDKN2B-AS1 PSRC1 RP1-257A7.5 SLC22A3
HDL Cholesterol 3.88 2 1 2.2 0.00 1.0e+00 PSRC1 RP11-731C17.2
LDL Cholesterol 64.06 2 1 2.2 0.00 1.0e+00 PSRC1 RP11-288H12.3
Schizophrenia (2014) 4.26 2 1 2.2 0.00 1.0e+00 FES RP11-731C17.2
Triglycerides 3.37 2 0 0.0 0.00 1.0e+00 RP11-288H12.3 RP11-731C17.2
Type 2 Diabetes (T2D) (2012) 3.29 1 0 0.0 0.00 1.0e+00 CDKN2B
Blood Eosinophil Count 0.59 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Blood Platelet Count 1.16 3 1 2.2 0.00 1.0e+00 CDKN2B RP11-731C17.2 SLC22A3
Blood Red Count 0.65 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Blood White Count 1.96 4 2 4.4 0.54 4.6e-01 CDKN2B FES RP11-731C17.2 RP1-257A7.5
Heel T-Score 0.59 1 0 0.0 0.00 1.0e+00 PSRC1
BMI 2.36 3 1 2.2 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Height 1.45 5 5 11.1 -0.98 3.5e-03 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Waist Hip Ratio (WHR) 2.91 4 1 2.2 0.91 8.7e-02 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 SLC22A3
Systolic Blood Pressure 7.78 3 2 4.4 0.00 1.0e+00 FES RP1-257A7.5 SLC22A3
Smoking Status 2.19 1 0 0.0 0.00 1.0e+00 FES
Allergy or Eczema 1.53 1 0 0.0 0.00 1.0e+00 FES
Cardiovascular Disease 11.84 5 3 6.7 0.98 2.3e-03 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Respiratory disease 1.87 1 0 0.0 0.00 1.0e+00 FES
Type 2 Diabetes (T2D) (2018) 2.53 2 0 0.0 0.00 1.0e+00 RP11-731C17.2 SLC22A3
Lung FEV1/FVC ratio 1.55 2 2 4.4 0.00 1.0e+00 PSRC1 RP11-378J18.8
Lung FVC 0.79 1 0 0.0 0.00 1.0e+00 RP11-378J18.8
Hair Pigment 0.60 3 3 6.7 0.00 1.0e+00 CDKN2B CDKN2B-AS1 FES
Hand grip strength (left) 2.27 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Number of treatments/medications taken 4.62 3 0 0.0 0.00 1.0e+00 FES PSRC1 RP11-731C17.2
Sensitivity / hurt feelings 2.31 1 1 2.2 0.00 1.0e+00 FES
Hearing difficulty/problems: Yes 2.06 1 0 0.0 0.00 1.0e+00 RP11-378J18.8
Relative age of first facial hair 2.17 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Systolic blood pressure, automated reading 6.97 2 2 4.4 0.00 1.0e+00 FES RP1-257A7.5
Angina 30.02 8 5 11.1 0.96 1.5e-04 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A3
Medication: Metformin 2.40 1 0 0.0 0.00 1.0e+00 CDKN2B
Impedance of leg (right) 2.06 3 1 2.2 0.00 1.0e+00 FES RP11-378J18.8 RP11-731C17.2
Leg fat-free mass (left) 1.57 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Trunk fat percentage 1.69 2 0 0.0 0.00 1.0e+00 RP1-257A7.5 SLC22A3
Hand grip strength (right) 1.85 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Relative age voice broke 2.03 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
High blood pressure 8.55 3 1 2.2 0.00 1.0e+00 FES RP11-731C17.2 RP1-257A7.5
Hayfever, allergic rhinitis or eczema 1.54 1 0 0.0 0.00 1.0e+00 FES
Medication: Atenolol 7.61 2 1 2.2 0.00 1.0e+00 CDKN2B FES
Sitting height 0.86 2 0 0.0 0.00 1.0e+00 FES SLC22A3
High blood pressure (mother) 9.10 2 1 2.2 0.00 1.0e+00 FES RP1-257A7.5
Body mass index (BMI) 1.84 2 1 2.2 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Impedance of leg (left) 1.98 3 1 2.2 0.00 1.0e+00 FES RP11-378J18.8 RP11-731C17.2
Leg predicted mass (left) 1.57 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Trunk fat mass 1.80 2 0 0.0 0.00 1.0e+00 RP1-257A7.5 SLC22A3
Waist circumference 2.04 2 1 2.2 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Number of incorrect matches in round 2.27 1 0 0.0 0.00 1.0e+00 FES
Past tobacco smoking 2.82 1 0 0.0 0.00 1.0e+00 CDKN2B-AS1
Alcohol usually taken with meals 2.03 1 0 0.0 0.00 1.0e+00 FES
Nervous feelings 1.63 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Heart attack 33.67 9 8 17.8 1.00 2.2e-13 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 RP1-257A7.5 SLC22A3
Allergy 1.59 1 0 0.0 0.00 1.0e+00 FES
Medication: Ramipril 5.92 1 0 0.0 0.00 1.0e+00 FES
Medication: Simvastatin 20.02 6 2 4.4 0.94 4.9e-03 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-731C17.2 SLC22A3
Illnesses of siblings 3.99 1 1 2.2 0.00 1.0e+00 FES
Weight 1.62 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Impedance of arm (right) 2.19 2 1 2.2 0.00 1.0e+00 CDKN2B RP11-731C17.2
Arm fat percentage (right) 1.88 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Trunk fat-free mass 1.36 2 1 2.2 0.00 1.0e+00 PSRC1 SLC22A3
Hip circumference 2.06 2 1 2.2 0.00 1.0e+00 RP11-731C17.2 SLC22A3
Father's age at death 8.08 4 1 2.2 -1.00 3.1e-03 CDKN2B CDKN2B-AS1 FES PSRC1
Falls in the last year 2.35 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Number of live births 1.11 1 0 0.0 0.00 1.0e+00 FES
Noisy workplace 2.60 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Asthma 1.39 1 0 0.0 0.00 1.0e+00 FES
Medication: Ibuprofen (e.g. Nurofen) 5.93 3 1 2.2 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Medication: Cholesterol lowering 29.70 8 3 6.7 0.88 3.7e-03 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 SLC22A3
Illnesses of mother 6.65 2 1 2.2 0.00 1.0e+00 CDKN2B FES
Pulse wave Arterial Stiffness index 4.96 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Impedance of arm (left) 1.63 1 1 2.2 0.00 1.0e+00 RP11-731C17.2
Arm fat mass (right) 1.84 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Trunk predicted mass 1.34 2 1 2.2 0.00 1.0e+00 PSRC1 SLC22A3
Standing height 1.44 4 2 4.4 -0.98 1.6e-02 PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Breastfed as a baby 1.96 1 0 0.0 0.00 1.0e+00 FES
Hair/balding pattern: Pattern 4 1.53 1 0 0.0 0.00 1.0e+00 FES
Birth weight of first child 4.86 1 1 2.2 0.00 1.0e+00 FES
Medication: Paracetamol 3.06 1 1 2.2 0.00 1.0e+00 RP1-257A7.5
Headache pain in last month 5.79 2 1 2.2 0.00 1.0e+00 FES RP1-257A7.5
Medication for cholesterol, blood pressure or diabetes 13.87 4 2 4.4 -0.85 1.5e-01 FES PSRC1 RP11-378J18.8 RP11-731C17.2
Glaucoma (self-reported) 7.26 2 1 2.2 0.00 1.0e+00 CDKN2B CDKN2B-AS1
Medication: Amlodipine 3.47 1 1 2.2 0.00 1.0e+00 FES
Birth weight 3.00 1 1 2.2 0.00 1.0e+00 FES
High blood pressure (siblings) 3.82 1 1 2.2 0.00 1.0e+00 FES
Body fat percentage 1.83 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Leg fat percentage (right) 2.35 2 1 2.2 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Arm fat-free mass (right) 1.34 3 0 0.0 0.00 1.0e+00 PSRC1 RP11-731C17.2 SLC22A3
Wheeze or whistling in the chest in last year 1.35 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Pulse wave peak to peak time 4.99 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Qualifications: College or University degree 1.01 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Medication for pain relief, constipation, heartburn 4.19 3 0 0.0 0.00 1.0e+00 PSRC1 RP11-731C17.2 RP1-257A7.5
Neck or shoulder pain in last month 2.49 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Medication: Blood pressure 7.13 1 1 2.2 0.00 1.0e+00 FES
Angina (self-reported) 31.15 8 5 11.1 0.96 1.2e-04 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A3
Migraine (self-reported) 5.75 1 1 2.2 0.00 1.0e+00 RP1-257A7.5
Medication: Ibuprofen 5.79 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Mean time to correctly identify matches 2.04 1 0 0.0 0.00 1.0e+00 FES
Heart disease (mother) 14.77 7 2 4.4 0.98 1.2e-04 CDKN2B CDKN2B-AS1 FES RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A3
Whole body fat mass 1.91 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Leg fat mass (right) 1.91 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Arm predicted mass (right) 1.41 3 0 0.0 0.00 1.0e+00 PSRC1 RP11-731C17.2 SLC22A3
Pulse rate, automated reading 1.75 2 0 0.0 0.00 1.0e+00 RP11-378J18.8 RP1-257A7.5
Alcohol intake frequency. 2.08 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Comparative height size at age 10 1.37 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Chest pain or discomfort 3.55 1 0 0.0 0.00 1.0e+00 CDKN2B
Medication: Aspirin 17.94 7 5 11.1 0.99 5.9e-06 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Knee pain experienced in last month 1.41 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Hypertension (Self-reported) 8.84 4 1 2.2 0.43 5.7e-01 FES RP11-731C17.2 RP1-257A7.5 SLC22A3
Illnesses of father: Heart disease 31.50 9 6 13.3 0.96 3.1e-05 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 RP1-257A7.5 SLC22A3
Smoking status: Previous 2.63 1 0 0.0 0.00 1.0e+00 CDKN2B-AS1
Whole body fat-free mass 1.43 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Leg fat-free mass (right) 1.59 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Arm fat percentage (left) 1.85 2 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Handedness (chirality/laterality): Left-handed 1.72 1 0 0.0 0.00 1.0e+00 FES
Long-standing illness, disability or infirmity 2.51 1 0 0.0 0.00 1.0e+00 CDKN2B
Diabetes diagnosed by doctor 1.90 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication for cholesterol 7.49 3 1 2.2 0.00 1.0e+00 FES PSRC1 SLC22A3
Mineral and other dietary supplements 2.74 1 0 0.0 0.00 1.0e+00 FES
Breast cancer (self-reported) 2.54 1 0 0.0 0.00 1.0e+00 CDKN2B
Asthma (self-reported) 1.44 1 0 0.0 0.00 1.0e+00 FES
Medication: Aspirin 18.20 7 5 11.1 0.99 4.4e-06 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Illnesses of father: None of the above (group 1) 12.38 5 2 4.4 -0.99 6.0e-04 CDKN2B CDKN2B-AS1 FES RP11-731C17.2 SLC22A3
Whole body water mass 1.39 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Leg predicted mass (right) 1.60 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Arm fat mass (left) 1.85 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Number of self-reported non-cancer illnesses 3.12 1 0 0.0 0.00 1.0e+00 PSRC1
Average weekly champagne plus white wine intake 1.42 1 0 0.0 0.00 1.0e+00 RP11-288H12.3
Eye problems/disorders: Glaucoma 9.22 2 2 4.4 0.00 1.0e+00 CDKN2B CDKN2B-AS1
Medication: Blood pressure 7.13 2 1 2.2 0.00 1.0e+00 FES SLC22A3
Supplements: Fish oil (including cod liver oil) 3.01 1 0 0.0 0.00 1.0e+00 SLC22A3
High cholesterol (Self-reported) 30.66 6 3 6.7 0.79 6.3e-02 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 SLC22A3
Medication: Bendroflumethiazide 3.32 1 1 2.2 0.00 1.0e+00 FES
Medication: Paracetamol 2.47 2 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Medication: Lisinopril 2.38 1 0 0.0 0.00 1.0e+00 FES
Medication: Atorvastatin 20.51 5 2 4.4 0.99 1.4e-03 CDKN2B CDKN2B-AS1 PSRC1 RP11-288H12.3 SLC22A3
Illnesses of father: High blood pressure 5.90 1 1 2.2 0.00 1.0e+00 FES
Ever smoked 2.15 1 0 0.0 0.00 1.0e+00 FES
Basal metabolic rate 1.47 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Leg fat percentage (left) 2.02 2 1 2.2 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Arm fat-free mass (left) 1.20 2 0 0.0 0.00 1.0e+00 PSRC1 SLC22A3
Risk taking 3.77 2 0 0.0 0.00 1.0e+00 FES RP11-731C17.2
Age started oral contraceptive pill 1.62 1 0 0.0 0.00 1.0e+00 FES
Diastolic blood pressure, automated reading 6.22 3 1 2.2 0.00 1.0e+00 CDKN2B CDKN2B-AS1 FES
Vascular/heart problems diagnosed by doctor 10.48 4 1 2.2 -0.96 3.9e-02 CDKN2B FES RP11-731C17.2 SLC22A3
Cholesterol lowering medication 17.36 5 2 4.4 0.95 1.2e-02 CDKN2B PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Pain experienced in last month 1.87 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Basal cell carcinoma (self-reported) 3.08 1 0 0.0 0.00 1.0e+00 CDKN2B
Heart disease (siblings) 12.11 6 0 0.0 0.97 1.1e-03 CDKN2B-AS1 FES PSRC1 RP11-378J18.8 RP1-257A7.5 SLC22A3
Impedance of whole body 1.82 2 1 2.2 0.00 1.0e+00 PSRC1 RP11-731C17.2
Leg fat mass (left) 1.73 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Arm predicted mass (left) 1.31 2 0 0.0 0.00 1.0e+00 PSRC1 SLC22A3

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 1 0.029 1.3
GTEx Adipose Visceral Omentum 0 0.000 1.3
GTEx Adrenal Gland 0 0.000 1.3
GTEx Artery Aorta 3 0.101 1.4
GTEx Artery Coronary 1 0.085 1.4
GTEx Artery Tibial 4 0.106 1.4
GTEx Brain Caudate basal ganglia 0 0.000 1.3
GTEx Brain Cerebellar Hemisphere 3 0.201 1.3
GTEx Brain Cerebellum 1 0.050 1.4
GTEx Brain Cortex 0 0.000 1.3
GTEx Brain Frontal Cortex BA9 0 0.000 1.3
GTEx Brain Hippocampus 0 0.000 1.1
GTEx Brain Hypothalamus 1 0.169 1.3
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.2
GTEx Brain Putamen basal ganglia 0 0.000 1.4
GTEx Breast Mammary Tissue 1 0.051 1.3
GTEx Breast Mammary Tissue (Male) 0 0.000 1.3
GTEx Breast Mammary Tissue (Female) 1 0.061 1.2
GTEx Cells EBV-transformed lymphocytes 0 0.000 1.3
GTEx Cells Transformed fibroblasts 3 0.071 1.3
GTEx Colon Sigmoid 1 0.068 1.3
GTEx Colon Transverse 0 0.000 1.3
GTEx Esophagus Gastroesophageal Junction 1 0.069 1.3
GTEx Esophagus Mucosa 1 0.030 1.3
GTEx Esophagus Muscularis 2 0.062 1.3
GTEx Heart Atrial Appendage 0 0.000 1.3
GTEx Heart Left Ventricle 0 0.000 1.3
GTEx Liver 1 0.139 1.3
GTEx Lung 1 0.035 1.4
GTEx Muscle Skeletal 1 0.035 1.3
GTEx Nerve Tibial 2 0.046 1.3
GTEx Ovary 1 0.110 1.3
GTEx Pancreas 0 0.000 1.3
GTEx Pituitary 0 0.000 1.3
GTEx Prostate 1 0.120 1.3
GTEx Skin Not Sun Exposed Suprapubic 0 0.000 1.3
GTEx Skin Sun Exposed Lower leg 2 0.055 1.3
GTEx Small Intestine Terminal Ileum 0 0.000 1.3
GTEx Spleen 0 0.000 1.4
GTEx Stomach 0 0.000 1.4
GTEx Testis 0 0.000 1.2
GTEx Thyroid 0 0.000 1.3
GTEx Uterus 0 0.000 1.3
GTEx Vagina 0 0.000 1.4
GTEx Whole Blood 1 0.050 1.3
METSIM Adipose 0 0.000 1.3
NTR Blood 0 0.000 1.3
ROSMAP Brain Pre-frontal Cortex 1 0.023 1.3
YFS Blood 0 0.000 1.2
CommonMind Brain Pre-frontal Cortex 4 0.074 1.3
The Cancer Genome Atlas Bladder Urothelial Carcinoma 0 0.000 1.2
The Cancer Genome Atlas Breast Invasive Carcinoma 2 0.045 1.3
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 0 0.000 1.2
The Cancer Genome Atlas Colon Adenocarcinoma 0 0.000 1.3
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.2
The Cancer Genome Atlas Glioblastoma Multiforme 0 0.000 1.2
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 0 0.000 1.3
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 1 0.024 1.3
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 1 0.049 1.3
The Cancer Genome Atlas Brain Lower Grade Glioma 2 0.046 1.3
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.181 1.2
The Cancer Genome Atlas Lung Adenocarcinoma 0 0.000 1.3
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 0 0.000 1.3
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 0 0.000 1.2
The Cancer Genome Atlas Pancreatic Adenocarcinoma 0 0.000 1.3
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.4
The Cancer Genome Atlas Prostate Adenocarcinoma 0 0.000 1.3
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.2
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.2
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.3
The Cancer Genome Atlas Stomach Adenocarcinoma 0 0.000 1.3
The Cancer Genome Atlas Testicular Germ Cell Tumors 0 0.000 1.2
The Cancer Genome Atlas Thyroid Carcinoma 1 0.019 1.3
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.2